Navigation Links
Thoratec Comments on February 23rd Voluntary Medical Device Correction Notification
Date:4/4/2012

PLEASANTON, Calif., April 4, 2012  /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR) today commented on a recent voluntary medical device correction notification (the "Notification"), related to the bend relief component for the sealed outflow graft of the HeartMate II® Left Ventricular Assist System.   The company initiated the voluntary Notification to clinicians on February 23, 2012.  

Following the company's voluntary Notification to clinicians on February 23, 2012, the FDA posted information regarding the action on its website during the week of March 19th.  Today, this same information appeared in the news section of the FDA website.  However, today's posting was only a reference to the previous communication, and there was no new information provided. 

After initiating the Notification, Thoratec contacted all hospitals to whom HeartMate II sealed outflow grafts had been distributed.  The company's voluntary Notification was intended to provide information to clinicians, including a clarification of the instructions for use, and did not involve the return of any product.  Subsequently, the company received acknowledgment forms from surgeons at all such U.S. hospitals, verifying that clinicians have reviewed the Notification and understand the information provided. 

Thoratec anticipates no material financial impact from this action. 

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

Many of the preceding paragraphs, particularly but not exclusively those addressing future performance, contain forward-looking statements within the mean
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thoratec Presentation at Leerink Swann Healthcare Conference to be Webcast
2. Thoratec Schedules Fourth Quarter Conference Call, Webcast
3. Thoratec Announces Appointment of William A. Hawkins to Board of Directors
4. Thoratec Presentation at Oppenheimer Conference to Be Webcast
5. Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program
6. Thoratec Reports Third Quarter Fiscal 2011 Results
7. Thoratec Schedules Third Quarter Conference Call, Webcast
8. Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast
9. Thoratec Announces Presentations at Upcoming Investor Conferences
10. Thoratec Reports Second Quarter Revenue Increase of 17 Percent
11. Thoratec Announces Resignation of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... WASHINGTON , Sept. 22, 2014 ... deadline of Monday, Sept. 29 at 5 p.m. ... for Kids!" competition, in response to continued strong ... of $50,000 each will be awarded to the ... Pediatric Surgical Innovation Symposium hosted by Children,s National ...
(Date:9/22/2014)... 22, 2014  Elusys Therapeutics, Inc. (Elusys), a ... disease, today announced it has completed three phase ... (ETI-204). Obiltoxaximab is an anti-toxin in development for ... these studies support the safety and tolerability of ... intended therapeutic dose. The conclusion of these studies ...
(Date:9/22/2014)... , Sept. 22, 2014  Continua and ... in healthcare technology, media and telecommunications,  have formed ... China and promote international ... BHG announced this new partnership during the global ... Washington, DC , while also ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4
... There are some two dozen oncology therapies in Phase ... development. While only some of these therapies will make it ... a competitive marketplace where success revolves around planning as much ... in the oncology therapeutic area must constantly evaluate which factors ...
... April 20, 2012 A recent clinical trial conducted at ... drug used to treat Parkinson,s Disease greatly improves the quality ... such as tremors, slowness, stiffness and difficulty walking. ... hold the trial, which was led by Dr. C. Warren ...
Cached Medicine Technology:Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 3
(Date:9/22/2014)... 2014 As concerns about the ... morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries mount, ... the continued use of uterine morcellation by some ... discouraged these procedures. According to The Wall Street ... risks associated with power morcellators are overblown, and ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... new AS365 N3+ Dauphin, the latest version of Airbus ... is based at Miami Valley Hospital in ... medical transport helicopters. , “We have a lot of ... Vice President, Emergency, Trauma, and CareFlight. “We’ve been operating ...
(Date:9/22/2014)... 2014 PCI (Project Concern International) ... equip women around the world with tools and training ... Women Empowered (WE) Initiative announced at the CGI Annual ... to pool their savings, invest in their own businesses, ... to ending poverty in the world, and through our ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 The ... the Department of Surgery at the Icahn School of ... Doctors New York Group for Plastic Surgery gives residents ... access to a team of world-renowned plastic surgeons performing ... C. Andrew Salzberg, MD, who led NYGPS, was named ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global ... solutions. , WHAT: The 10th annual Customer Response ... for the connected consumer. Constant change in technology ... challenges and opportunities for customer experience executives. The ... practices, network and learn from fellow attendees, speakers ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... CLARA, Calif., January 8 Align Technology,Inc. (Nasdaq: ... that the,Company will report fourth quarter and fiscal year ... close of market. Financial results will,be released over PR ... the,Investor Relations section of the Company,s website at, http://investor.aligntech.com ...
... TEAC America, Inc. launches its,next generation P-55C dye-sublimation ... available, during the CES Show at,the Las Vegas Convention ... The P-55C printer can be integrated with 3 TEAC ... With TEAC,s,AL220S and AL550S, customers can print up to ...
... Vyvanse as the Clinical Gold Standard, According to ... 8 Decision Resources, one of the world,s ... and healthcare issues, finds that physicians indicate there ... effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder ...
... (Nasdaq: GHDX ) today announced the appointment ... president and chief operating officer,Popovits is now the president ... Cole has been appointed as chief operating officer and ... reporting to Popovits. , "Kim,s ...
... and FirstDoc (Documentum) Solutions Deliver Regulatory Document Management ... CSC (NYSE: CSC ) announced today ... content management (ECM) solutions, adding features designed to ... the document life cycle and the growing collaboration ...
... will force hospitals to reconsider or defer purchases ... GroupWALTHAM, Mass., Jan. 8 According to Millennium ... RIS, and CVIS 2009 report, the budgetary ... affect the markets for picture archiving and communication ...
Cached Medicine News:Health News:Align Technology to Announce Fourth Quarter and Fiscal Year 2008 Results on January 28, 2009 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 3Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 2Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 3Health News:Budgetary Constraints on Health Care Facilities to Affect PACS, RIS, and CVIS Markets 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: